Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Mr. Andrew Oxtoby est le Chief Executive Officer de Kalaris Therapeutics Inc, il a rejoint l'entreprise depuis 2025.
Quelle est la performance du prix de l'action KLRS ?
Le prix actuel de KLRS est de $4.82, il a 上升 de 1.9% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Kalaris Therapeutics Inc ?
Kalaris Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Kalaris Therapeutics Inc ?
La capitalisation boursière actuelle de Kalaris Therapeutics Inc est de $110.5M
Est-ce que Kalaris Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Kalaris Therapeutics Inc, y compris 4 achat fort, 3 achat, 2 maintien, 0 vente et 4 vente forte